Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin

References

• Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S, Yawo H. (1999). Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274:17159–17163.
   PubMed Web of Science ®Google Scholar
• Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, Kitahara M, Toyoda K, Sakashita M, Saito Y. (1997). Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 47:904–909.
   PubMed Web of Science ®Google Scholar
• Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K. (2008). Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther 83:251–257.
   PubMed Web of Science ®Google Scholar
• Choi MK, Shin HJ, Choi YL, Deng JW, Shin JG, Song IS. (2011). Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica 41:24–34.
   PubMed Web of Science ®Google Scholar
• Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, Jang IJ. (2005). Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78:342–350.
   PubMed Web of Science ®Google Scholar
• Cui Y, König J, Leier I, Buchholz U, Keppler D. (2001). Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626–9630.
   PubMed Web of Science ®Google Scholar
• Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, Shin JG. (2008). The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: The contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 18:424–433.
   PubMed Web of Science ®Google Scholar
• Fujino H, Yamada I, Shimada S, Nagao T, Yoneda M. (2002). Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. Arzneimittelforschung 52:745–753.
   PubMed Web of Science ®Google Scholar
• Fujino H, Yamada I, Shimada S, Yoneda M, Kojima J. (2003). Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 33:27–41.
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139–146.
   PubMed Web of Science ®Google Scholar
• Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG. (1999). A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161–37168.
   PubMed Web of Science ®Google Scholar
• Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y. (2007). SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 82:541–547.
   PubMed Web of Science ®Google Scholar
• Kajinami K, Mabuchi H, Saito Y. (2000). NK-104: A novel synthetic HMG-CoA reductase inhibitor. Expert Opin Investig Drugs 9:2653–2661.
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. (2009). Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693–705.
   PubMed Web of Science ®Google Scholar
• Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. (2005). Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513–522.
   PubMed Web of Science ®Google Scholar
• Kimata H, Fujino H, Koide T. (1998). Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Xenobio Metab Dispos 13:484–98.
   Google Scholar
• Kojima J, Fujino H, Abe H, Yosimura M, Kanda H, Kimata H. (1999). Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biol Pharm Bull 22:142–150.
   PubMed Web of Science ®Google Scholar
• König J, Cui Y, Nies AT, Keppler D. (2000). A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278:G156–G164.
   PubMed Web of Science ®Google Scholar
• Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, Klein K, Eichelbaum M, Keppler D, Konig J. (2002). A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 277:43058–43063.
   PubMed Web of Science ®Google Scholar
• Mukhtar RY, Reid J, Reckless JP. (2005). Pitavastatin. Int J Clin Pract 59:239–252.
   PubMed Web of Science ®Google Scholar
• Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivistö KT. (2004). High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429–440.
   PubMedGoogle Scholar
• Niemi M. (2007). Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787–802.
   PubMed Web of Science ®Google Scholar
• Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y. (2003). Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554–565.
   PubMed Web of Science ®Google Scholar
• Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T. (2002). Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302:804–813.
   PubMed Web of Science ®Google Scholar
• Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. (2005). Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: In vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33:434–439.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen PJ, Niemi M. (2008). Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9:19–33.
   PubMed Web of Science ®Google Scholar
• Shimada S, Fujino H, Morikawa T, Moriyasu M, Kojima J. (2003). Uptake mechanism of pitavastatin, a new inhibitor of HMG-CoA reductase, in rat hepatocytes. Drug Metab Pharmacokinet 18:245–251.
   PubMedGoogle Scholar
• Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. (2000). Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273:251–260.
   PubMed Web of Science ®Google Scholar
• Tirona RG, Leake BF, Merino G, Kim RB. (2001). Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669–35675.
   PubMed Web of Science ®Google Scholar
• Tirona RG, Leake BF, Wolkoff AW, Kim RB. (2003). Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223–228.
   PubMed Web of Science ®Google Scholar
• Tirona RG. (2005). Ethnic differences in statin disposition. Clin Pharmacol Ther 78:311–316.
   PubMed Web of Science ®Google Scholar
• Yang GP, Yuan H, Tang B, Zhang W, Wang LS, Huang ZJ, Ou-Yang DS, Zhang GX, Zhou HH. (2010). Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients. Acta Pharmacol Sin 31:382–386.
   PubMed Web of Science ®Google Scholar